Hims & Hers Health Trading Volume Plummets 67.31% Ranking 51st Amid Legal Turmoil

On July 24, 2025, Hims & Hers Health (HIMS) experienced a significant decline, with its trading volume dropping by 67.31% to 15.02 billion, ranking 51st in the day's market activity. The stock price fell by 1.21%.

Hims & Hers Health, Inc. is currently facing multiple class action lawsuits. These legal actions allege that the company failed to disclose risks associated with its compounded drug offerings. The lawsuits claim that between April 29, 2025, and June 23, 2025, Hims & Hers did not inform investors about the deceptive promotion and selling of illegitimate, knockoff versions of Wegovy®, which posed risks to patient safety. This issue raised concerns about the potential termination of the company's collaboration with Novo Nordisk. Additionally, the lawsuits assert that Hims & Hers made false and misleading statements about its partnership with Novo Nordisk, including claims about the approval of compounded semaglutide products and the continued access to Wegovy for subscribers.

Investors who purchased Hims & Hers securities during the specified period are encouraged to join the class action lawsuits. The lead plaintiff deadline is set for August 25, 2025. Legal firms involved in these cases, such as Bronstein, Gewirtz & Grossman, LLC, are representing investors on a contingency fee basis, meaning they will only be compensated if the lawsuit is successful. These firms have a history of recovering significant amounts for investors in similar cases.